EMEA/H/C/000109 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 203 | 22q11.2 deletion syndrome | 1 |
203. 22q11.2 deletion syndrome
Clinical trials : 5 / Drugs : 7 - (DrugBank : 1) / Drug target genes : 14 - Drug target pathways : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-002011-61-NL (EUCTR) | 13/08/2021 | 21/06/2021 | Riluzole as treatment for psychotic and cognitive symptoms in 22q11.2 deletion syndrome | The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome - Riluzole in 22q11.2DS | 22q11.2 deletion syndrome;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03] | Trade Name: Rilutek Product Name: Riluzole Product Code: EMEA/H/C/000109 | Academisch ziekenhuis Maastricht | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 45 | Phase 3 | Netherlands |